Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2022 at "Endocrine journal"
DOI: 10.1507/endocrj.ej21-0696
Abstract: The insufficient activity of insulin and the hyperactivity of glucagon are responsible for glucose intolerance in patients with type 2 diabetes. Whereas sodium-glucose cotransporter-2 (SGLT2) inhibitors improve blood glucose levels in patients with type 2… read more here.
Keywords: patients type; effects luseogliflozin; secretion; luseogliflozin secretion ... See more keywords